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Abstract. Cases of ossification and increased bone mineral 
density (BMD) at sites of bone metastasis following zoledronic 
acid (ZA) treatment have not been reported. The current study 
presents the case of a 65-year-old patient with lung adenocarci-
noma and bone metastases in the lumbar vertebrae and femurs. 
Ossification and an increase in BMD at the metastatic sites 
was achieved following treatment with ZA and irradiation of 
the bone metastatic sites. The patient was able to maintain a 
normal lifestyle for over two years, despite the bone metas-
tases. Therefore, as treatment with ZA was demonstrated to 
improve patient quality of life, physicians should consider this 
treatment strategy, particularly for the treatment of metastasis 
in weight-bearing bones.
Introduction
Lumbar vertebrae and femur bone metastases are associated 
with an increased risk of fracture and a decreased quality of 
life for the affected individual (1,2). Zoledronic acid (ZA) is 
understood to prevent these risks by inhibiting the function 
of osteoclast cells; thus, reducing bone loss (3). Application of 
ZA and irradiation to the bone metastases have been hypoth-
esized to facilitate ossification and cause an increase in bone 
mineral density (BMD); however, to the best of our knowledge, 
these phenomena have not yet been reported. In addition to 
conventional irradiation, novel treatments, including systemic 
chemotherapy and molecular target agents, such as erlotinib 
and bervacizumab, have represented a significant advance in 
lung adenocarcinoma treatment (4,5). These novel treatment 
strategies combined with ZA are now recommended for the 
treatment of the majority of patients with lung adenocarci-
noma with bone metastasis (3,6). The current study presents 
the case of a patient with lung adenocarcinoma who exhib-
ited an increased BMD in the metastatic sites following ZA 
administration and irradiation. An increase in ossification 
was also observed. The patient was able to maintain a normal 
lifestyle for more than two years, despite the lumbar vertebrae 
and femur bone metastases. Written informed consent was 
obtained from the patient's family.
Case report
A 63-year-old female with no history of smoking was admitted 
to Mito Medical Center, University of Tsukuba‑Mito Kyodo 
General Hospital (Mito, Japan) after presenting with lumbago 
and pain around the hip joints for five months. At admission, 
chest radiography and computed tomography (CT) scans 
revealed a 3.5x2.5 cm mass in the lower right lobe of the lungs, 
with multiple intrapulmonary metastases (Fig. 1). Bone scans 
demonstrated marked accumulation of 99mTc in the vertebrae 
(C7, Th9, Th11, L1 and L2), femurs and ribs (Fig. 2). In addi-
tion, an abdominal CT scan revealed a metastatic nodule in 
the liver. Histopathological specimens, which were obtained 
bronchoscopically from the mass in the right lung, revealed 
an adenocarcinoma with an exon 19 deletion in the epidermal 
growth factor receptor (EGFR) gene. The patient received a 
total hip replacement due to a right femoral neck fracture. 
Subsequently, irradiation was applied to the metastatic sites in 
the lumbar vertebrae and femurs, and four courses of chemo-
therapy with carboplatin, pemetrexed and bevacizumab were 
administered. The patient received 4 mg ZA every month for 
24 months. The response to the chemotherapy was evaluated as 
a partial response; thereafter, the patient received 20 courses 
of maintenance chemotherapy with pemetrexed and bevaci-
zumab.
Ossification of the metastatic site in the left femoral 
neck was observed using plain radiography three months 
following the initiation of ZA treatment (Fig. 3). The BMD 
was measured by dual-energy X-ray absorptiometry (DEXA; 
DPX-Bravo; GE Healthcare, Tokyo Japan). Table I shows the 
change in the BMD prior to, at 8 months and at 20 months 
following the initiation of ZA administration. An increased 
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BMD was observed in the metastatic sites (L1, L2 and left 
femur), as well as the non-metastatic sites (L3 and L4). The 
patient did not undergo any adverse events following ZA 
treatment, including biphosphonate-associated osteonecrosis 
of the jaw (BRONJ), fever or renal toxicity. Following 
recurrence in the primary lesion and liver metastasis, the 
Figure 2. Bone scan at the time of first admission showing a marked accumulation of 99mTc in the vertebrae (C7, Th9, Th11, L1 and L2), femurs (arrow head) 
and ribs, as indicated by the arrows.
Figure 1. Chest computed tomography scan at the time of first admission showing a large mass in the right lower lobe of the lungs.
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patient received gefitinib therapy. The patient survived with 
no evidence of bone metastasis in other sites for two years. 
However, the patient had liver and pulmonary recurrence and 
succumbed to the disease three years following the diagnosis 
of lung adenocarcinoma.
Discussion
ZA is a third-generation nitrogen-containing parenteral 
bisphosphonate prescribed for the treatment of bone metas-
tases caused by solid tumors (7). In patients with lung 
cancer, ZA exhibits a favorable protective effect against 
skeletal-associated events, including bone fracture and severe 
pain requiring irradiation and opioids (7). Although ZA has 
a well-established tolerability profile and may be adminis-
tered safely as a long-term therapy, preventive measures are 
required to avoid a number of severe side effects, including 
BRONJ and renal toxicity, which have been observed in a 
small number of patients receiving long-term therapy (8). 
BRONJ is characterized by the unexpected appearance of 
necrotic bone in the oral cavity (8). In the current patient, 
cyclic administration of intravenous ZA resulted in ossifica-
tion and an increase in the BMD of the lumbar spine and 
femur bone. The observations of the present study revealed 
that the use of ZA was associated with a clinical and radio-
logical benefit. The patient also underwent irradiation therapy 
on the metastatic sites, platinum-based chemotherapy and 
gefitinib therapy. Apparent ossification with an improve-
ment in the BMD was observed following the completion 
of irradiation, and the treatment was continued with ZA 
and systemic chemotherapy. Although the most effective 
treatment strategies for metastases remain unknown, it was 
hypothesized that ZA had an important effect on a favorable 
outcome without any adverse side effects, including BRONJ. 
Bone metastasis has been identified as one of the unfavor-
able prognostic factors in patients with lung cancer (9). 
Figure 3. Plain radiography images showing changes in the metastatic site of the left femoral neck at (A) pretreatment, (B) 13 months following ZA initiation 
and (C) 21 months following ZA initiation. ZA, zoledronic acid.
Table I. Change in the BMD prior to and following the initiation of treatment with ZA.
       BMD (g/cm2)
 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Site Pretreatment 8‑months from ZA initiation 20‑months from ZA initiation
Lumbar spine
  L1 0.659 1.260 1.363
  L2 0.654 1.706 1.970
  L3 0.655 1.029 1.231
  L4 0.767 0.917 0.949
Neck of left femur 0.772 0.779 0.849
BMD, bone mineral density; ZA, zoledronic acid.
  C  B  A
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However, in the present study, the patient was found to have 
a mutation in the EGFR gene, which was evaluated as a 
favorable prognostic factor. Long-term survivors with bone 
metastasis have rarely been reported (10), and the incidence 
rate of complete remission from bone metastasis in patients 
with non‑small‑cell lung carcinoma (NSCLC) is low (11). 
Although currently rare, treatment with ZA for lung cancer 
patients with bone metastasis, particularly for those that are 
indicative for other intensive therapies, including the patient 
in the present study, should be considered for future cases.
There have been a few reported cases of ossification at the 
metastatic site following administration of ZA (12). Kawai et al 
reported a patient with large cell lung cancer who received 
ZA treatment and subsequently exhibited marked regression 
of the thoracic vertebrae following irradiation applied to the 
metastatic site (12). Ikeda et al also presented two cases of 
patients with NSCLC who were successfully treated with 
irradiation applied to the metastatic sites, systemic chemo-
therapy and ZA (13). Ossification in the thoracic spine of one 
patient and in the rib of the other patient were observed (13). 
The BMD, as measured by DEXA, increases with the admin-
istration of ZA in post‑menopausal osteoporosis patients (14), 
pediatric patients with spinal cord injury (15) and children 
with type III osteogenesis imperfecta (16). However, to the 
best of our knowledge, no study has revealed an improved 
BMD in the metastatic sites following the administration of 
ZA.
In conclusion, the results of the present study indicated 
that ZA enhanced ossification in the metastatic sites. In 
addition, an increase in the BMD occurred as a result of 
the formation of the metastatic bone lesions by irradiation, 
systemic chemotherapy and ZA. As the patient was able to 
maintain a normal lifestyle following treatment, the new bone 
appeared to have similar mechanical properties to that of 
normal non-metastatic bone. However, whether the increase 
in BMD with ossification in metastatic sites depends only on 
the efficacy of ZA remains inconclusive. Nonetheless, thera-
pies that include ZA have been shown to improve the quality 
of life of patients; thus, should be considered for the treatment 
of bone metastasis, whilst considering potential side effects, 
such as BRONJ.
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